Later on, a family of structurally diverse, high-affinity, sigma-2 ligands (S2L) were found to rapidly internalize into cancer cells, enabling the design of cancer-selective therapeutics that can achieve maximum treatment benefits while minimizing systemic toxicities [5, 6]. The gene discussed is AP2S1; the disease is cancer.